Design and Discovery of Novel Cyclic Peptides as EDPs–EBP Interaction Inhibitors for the Treatment of Liver Fibrosis-Reference-Cited by-同舟云学术

Design and Discovery of Novel Cyclic Peptides as EDPs–EBP Interaction Inhibitors for the Treatment of Liver Fibrosis

Published:2023-03-20 Issue:7 Volume:66 Page:4689-4702
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Song Nazi¹,Li Haonan¹,Tang Qinglin¹²,Luo Suijia²,Shi Zihan¹,Zhao Qian¹,Li Runkai³,Chen Yili³,Cai Xiaoqing¹^ORCID,Jiang Xianxing¹^ORCID

Affiliation:

1. Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China

2. Shenzhen Turier Biotech. Co. Ltd, Shenzhen 518000, China

3. Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University, and NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou 511400, China

Funder

Guangzhou Science and Technology Program key projects

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01764

Reference35 articles.

1. Molecular and cellular mechanisms of liver fibrosis and its regression

2. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues

3. Mechanisms of fibrosis: therapeutic translation for fibrotic disease

4. Liver fibrosis and repair: immune regulation of wound healing in a solid organ

5. AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis;Journal of Medicinal Chemistry;2024-07-11

2. Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment;Journal of Medicinal Chemistry;2024-04-08

3. Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment;Journal of Medicinal Chemistry;2023-06-06